Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod-Reference-Cited by-同舟云学术

Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod

Published:2019-06-12 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Rozenblit Mariya,Hendrickx Wouter^ORCID,Heguy Adriana,Chiriboga Luis^ORCID,Loomis Cynthia,Ray Karina^ORCID,Darvishian Farbod,Egeblad Mikala,Demaria Sandra^ORCID,Marincola Francesco M.,Bedognetti Davide,Adams Sylvia

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-42784-9.pdf

Reference48 articles.

1. Tan, A. R. Cutaneous manifestations of breast cancer. Semin. Oncol. 43, 331–334 (2016).

2. Takeda, K. & Akira, S. TLR signaling pathways. Seminars in Immunology 16, 3–9 (2004).

3. Weeks, C. E. & Gibson, S. J. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J. Interferon Res. 14, 81–85 (1994).

4. Urosevic, M. et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J. Natl. Cancer Inst. 97, 1143–1153 (2005).

5. Schön, M. et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J. Natl. Cancer Inst. 95, 1138–1149 (2003).

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer;International Journal of Molecular Sciences;2023-06-29

2. An integrated tumor, immune and microbiome atlas of colon cancer;Nature Medicine;2023-05

3. Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers;Frontiers in Endocrinology;2023-04-27

4. In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis;2022-09-13

5. Innate immunity as a target for novel therapeutics in triple negative breast cancer;Expert Opinion on Investigational Drugs;2022-07-12